Orion Corporation's Recent Study Outcome on ODM-105
Orion Corporation has revealed that its Phase 2 clinical study involving ODM-105, a potential treatment for insomnia, did not fulfill the primary objectives. With this development, the company has decided to discontinue the drug's advancement for this particular condition.
Understanding the Study's Findings
The trial, known as the UNITAS study, was designed to evaluate the effectiveness of ODM-105 (tasipimidine) against a placebo in a diverse group of adults diagnosed with insomnia disorder. Unfortunately, the results indicated that ODM-105 did not lead to significant improvements in key insomnia symptoms, including the time taken to fall asleep and overall sleep duration.
Despite this setback, it’s worth noting that ODM-105 demonstrated a favorable safety profile and was generally well tolerated by the participants. The final safety data and more comprehensive results are still pending, as the research team wants to ensure an accurate assessment of the findings before making further announcements.
Insights from Orion’s Leadership
Professor Outi Vaarala, the Executive Vice President of Innovative Medicines and Research & Development at Orion, expressed disappointment over the study's results, stating, "Our biggest regret is that we’re not able to provide a new and more efficient treatment option for people suffering from insomnia. The swift recruitment for the UNITAS study underscores the pressing need for innovative insomnia treatments."
She further emphasized the company's commitment to redirect their focus towards other promising projects within their research and clinical pipelines, hinting at a strategic shift in their developmental priorities.
A Closer Look at the UNITAS Study
The UNITAS study was a Phase 2b trial characterized by being randomized, triple-blind, and placebo-controlled. A total of 153 adult participants were enrolled for the evaluation. The primary endpoints were wake after sleep onset (WASO) and latency to persistent sleep (LPS), which were carefully monitored through polysomnography methods.
Orion's Future Directions and Focus on Other Therapies
In light of the recent results, Orion Corporation plans to reallocate its resources towards other developmental assets that show more promise in clinical research. The company has a robust portfolio that encompasses a wide range of therapeutic areas, including oncology and pain management.
Founded over a century ago, Orion Corporation has long been dedicated to enhancing individual well-being through the development, manufacturing, and marketing of both human and veterinary pharmaceuticals along with active pharmaceutical ingredients. The company has successfully created a diverse array of proprietary and generic medications, aimed at addressing a variety of health concerns.
Contact Information for Inquiries
For more details regarding this announcement or other inquiries, please reach out to:
Tuukka Hirvonen, Head of Investor Relations,
Orion Corporation,
Tel: +358 10 426 2721
Frequently Asked Questions
What was the primary goal of Orion's ODM-105 study?
The primary goal was to evaluate the effectiveness of ODM-105 in improving insomnia-related symptoms compared to placebo.
What were the results of the UNITAS study?
ODM-105 did not significantly improve symptoms like time to fall asleep and sleep duration in comparison to the placebo group.
What will happen to ODM-105 following these results?
Orion Corporation has decided to discontinue the development of ODM-105 for the treatment of insomnia.
How has Orion Corporation performed in the pharmaceutical industry?
Orion has maintained a strong presence in the pharmaceutical industry for over a century and continues to focus on developing various therapies, particularly in oncology and pain management.
Who can I contact for more information about Orion Corporation?
For inquiries, please contact Tuukka Hirvonen, Head of Investor Relations, at Orion Corporation.
